Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Add To Watchlist

Recent & Breaking News (NYSE:BMY)

Galectin Therapeutics Leaps Ahead with SBH Sciences Partnership

Accesswire February 13, 2014

Mid-Atlantic Lays Claim to Majority of Pharma-Biotech's $3.5 Billion Investment in Construction Starts in First-Quarter 2014, an Industrial Info News Alert

Marketwired February 11, 2014

BullTrends.com Releases Hot Stock Alerts on - BMY, GTAT, CANN, and HEMP

Accesswire February 11, 2014

Bristol-Myers Squibb to Take Part in Leerink Swann Global Health Care Conference

Business Wire February 5, 2014

Bristol-Myers Squibb Completes Previously Announced Sale of Global Diabetes Business to AstraZeneca

Business Wire February 3, 2014

Immuneering Corporation Expands Alliance with Bristol-Myers Squibb

PR Newswire January 29, 2014

Wall Street Fundamentals Releases New In-Depth Stock Reports on BMY, KMB, PG and SWK

Accesswire January 27, 2014

Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results

Business Wire January 24, 2014

Pharm-Bio Building Boom: More Than $20 Billion Set for 2014 North American Capital Project Starts, an Industrial Info News Alert

Marketwired January 17, 2014

AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American Diabetes Association's Pathway to Stop Diabetes Research Initiative

Business Wire January 16, 2014

Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis

Globe Newswire January 13, 2014

U.S. FDA Approves Farxiga(TM) (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes

Business Wire January 13, 2014

AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga(TM) (dapagliflozin)

Business Wire January 8, 2014

Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency

Business Wire January 8, 2014

Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2013 on January 24

Business Wire January 6, 2014

Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference

Business Wire January 6, 2014

Bristol-Myers Squibb to Take Part in Goldman Sachs Healthcare CEOs Unscripted Conference

Business Wire January 3, 2014

Obesity Stock Plays Standing Out from the Crowd

Accesswire December 20, 2013

FDA Accepts For Review ELIQUIS® (apixaban) Supplemental New Drug Application for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE

Business Wire December 19, 2013

Bristol-Myers Squibb Announces Dividend Increase

Business Wire December 19, 2013